Literature DB >> 7825222

Immunity and morbidity in human schistosomiasis mansoni.

A E Butterworth1, A J Curry, D W Dunne, A J Fulford, G Kimani, H C Kariuki, R Klumpp, D Koech, G Mbugua, J H Ouma.   

Abstract

This paper reviews the results of a longitudinal, multidisciplinary study on schistosomiasis mansoni that has been in progress in Machakos District, Kenya, since 1980. Different methods of delivering chemotherapy have been compared in a medium scale operational control programme. It is concluded that treatment only of infected children is an effective and feasible means of control, the frequency of treatment depending on the severity of disease. Within the framework of this programme, detailed studies have been undertaken of immunity to reinfection after treatment and of the reasons for differences in observed morbidity between different areas. An apparent resistance to reinfection, especially in older individuals, may be attributable to the protective effect of IgE antibodies against adult worm antigens. Various factors other than intensity of infection may contribute to severe morbidity, including parasite strain differences, interactions with other infections, nutritional status, and abnormalities in the regulation of pathogenic immune responses to egg antigens.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7825222

Source DB:  PubMed          Journal:  Trop Geogr Med        ISSN: 0041-3232


  21 in total

1.  Human immune responses to Schistosoma mansoni vaccine candidate antigens.

Authors:  A Ribeiro de Jesus; I Araújo; O Bacellar; A Magalhães; E Pearce; D Harn; M Strand; E M Carvalho
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

Review 2.  Immunology of parasitic helminth infections.

Authors:  Andrew S MacDonald; Maria Ilma Araujo; Edward J Pearce
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

3.  Differential liver protein expression during schistosomiasis.

Authors:  Marina Harvie; Thomas William Jordan; Anne Camille La Flamme
Journal:  Infect Immun       Date:  2006-11-13       Impact factor: 3.441

4.  Cellular and humoral immune responses and protection against schistosomes induced by a radiation-attenuated vaccine in chimpanzees.

Authors:  M Eberl; J A Langermans; P A Frost; R A Vervenne; G J van Dam; A M Deelder; A W Thomas; P S Coulson; R A Wilson
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

5.  Role of gamma interferon in the pathogenesis of severe schistosomiasis in interleukin-4-deficient mice.

Authors:  A C La Flamme; E A Patton; E J Pearce
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

Review 6.  The hygiene theory harnessing helminths and their ova to treat autoimmunity.

Authors:  Dana Ben-Ami Shor; Michal Harel; Rami Eliakim; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

7.  Symptomatic human neurocysticercosis--age, sex and exposure factors relating with disease heterogeneity.

Authors:  Agnès Fleury; Alain Dessein; Pierre Marie Preux; Michel Dumas; Graciela Tapia; Carlos Larralde; Edda Sciutto
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

8.  Schistosoma haematobium treatment in 1-5 year old children: safety and efficacy of the antihelminthic drug praziquantel.

Authors:  Francisca Mutapi; Nadine Rujeni; Claire Bourke; Kate Mitchell; Laura Appleby; Norman Nausch; Nicholas Midzi; Takafira Mduluza
Journal:  PLoS Negl Trop Dis       Date:  2011-05-17

9.  Schistosomiasis decreases central nervous system inflammation and alters the progression of experimental autoimmune encephalomyelitis.

Authors:  Anne Camille La Flamme; Kate Ruddenklau; B Thomas Bäckström
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

10.  T regulatory cell levels decrease in people infected with Schistosoma mansoni on effective treatment.

Authors:  Kanji Watanabe; Pauline N M Mwinzi; Carla L Black; Erick M O Muok; Diana M S Karanja; W Evan Secor; Daniel G Colley
Journal:  Am J Trop Med Hyg       Date:  2007-10       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.